IL1B and Hyperglycemia: Tonabersat, a connexin hemichannel blocker, can inhibit NLRP3 and lysed Caspase-1 complex formation with hyperglycemia and cytokine activation while preventing the release of the proinflammatory cytokines IL-1β, VEGF, and IL-6 (173).